SAVR in dialysis patients was associated with higher 1-month MACCE (HR 1.96; 95% CI 1.18-2.47) but lower 5-year mortality (HR 0.71; 95% CI 0.54-0.94) compared to TAVR.
Cohort (n=448)
Sí
Does surgical aortic valve replacement improve long-term survival compared to transcatheter aortic valve replacement in dialysis-dependent patients?
In dialysis-dependent patients, SAVR carries a higher early periprocedural risk but offers a significant long-term survival advantage at 3 and 5 years compared to TAVR.
Estimación del efecto: HR 0.71 (95% CI 0.54-0.94)
OBJECTIVE: To compare morbidity and mortality outcomes of isolated surgical aortic valve replacement (SAVR) versus transcatheter aortic valve replacement (TAVR) among patients on dialysis over 5 years. METHODS: Patients with CKD on dialysis undergoing isolated SAVR or TAVR between 2005 and 2025 were identified from the TriNetX Research Network. Cohorts were matched on demographics and relevant comorbidities. Baseline characteristics were compared using Chi-square and Wilcoxon rank-sum tests for categorical and continuous variables, respectively. Early outcomes were analyzed using logistic regression. Long-term outcomes at 1, 3, and 5 years were assessed using Kaplan-Meier survival analysis and Cox proportional hazards regression. RESULTS: After matching, 224 patients were included in each group with adequate balance. At 1 month, pooled 3-point major adverse cardiovascular and cerebrovascular events (MACCE; mortality, ischemic stroke, and acute MI) was significantly higher in the SAVR cohort (HR 1.96, 95%CI 1.18-2.47). Mortality did not significantly differ between cohorts at 1 year; however, it was significantly lower at 3 (HR=0.70, 95%CI 0.52-0.95) and 5 years (HR=0.71, 95%CI 0.54-0.94) with SAVR. Risk of atrial fibrillation was higher with SAVR at 1 month (OR=1.64; 95%CI 1.09-2.47). Other cardiovascular comorbidities were similar between the cohorts over the follow-up duration. CONCLUSION: In dialysis-dependent patients, SAVR is associated with higher early MACCE, but improved long-term survival compared with TAVR.
Tahhan et al. (Fri,) conducted a cohort in Dialysis-dependent chronic kidney disease requiring aortic valve replacement (n=448). Surgical aortic valve replacement (SAVR) vs. Transcatheter aortic valve replacement (TAVR) was evaluated on Mortality at 5 years (HR 0.71, 95% CI 0.54-0.94). SAVR in dialysis patients was associated with higher 1-month MACCE (HR 1.96; 95% CI 1.18-2.47) but lower 5-year mortality (HR 0.71; 95% CI 0.54-0.94) compared to TAVR.